of functions, e.g. promoting cell growth and differentiation, mediating cell-cell adhesion, and serving as signalling receptors (1) . The mode of action depends on the concentration and distribution of GSLs in the membrane. Up to 400 different GSLs have been identified that vary in their sugar chain-structure (2) . One of the main precursors for GSLs is glucosylceramide (GlcCer). GlcCer is synthesized by glucosylation of ceramide via a glucosylceramide synthase (GCS) at the cytosolic side of the Golgi complex (3) (4) (5) . Higher-order GSLs are formed by adding monosaccharides to the glucosyl headgroup in the Golgi lumen (6, 7) . These modifications require GlcCer transport from the cytosolic to the lumenal side of the Golgi. Two models of GlcCer transport have been proposed. One model suggests that GlcCer reaches the lumenal side at the endoplasmatic reticulum (ER) rather than at the Golgi (8, 9) . According to this model, GlcCer is first transported to the ER by FAPP2 (phosphatidylinositol 4-phosphate adaptor protein) and then flipped to the lumenal side by low-specificity phospholipid flippases (8, 9) . From the ER, GlcCer reaches the Golgi lumenal side by vesicular transport. Another model also involves FAPP2, but here FAPP2 transports GlcCer from the cis-Golgi (CGN) to the transGolgi network (TGN), where a yet unidentified transporter flips GlcCer to the lumenal side (10) . Apart from these two pathways, a fraction of GlcCer is also transported to the plasma membrane via non-vesicular transport, where it is inserted into the cytosolic membrane leaflet (9) . Transport of GlcCer to the plasma membrane has been proposed to involve FAPP2 and another glucosylceramide transfer-protein GLTP (glycolipid transfer protein) (9) .
GlcCer is degraded to glucose and ceramide by three different hydrolases: the lysosomal GBA1 and the non-lysosomal GBA2 and GBA3 (11) (12) (13) (14) (15) (16) . The three GBA proteins show no structural or sequence homology, but share a similar enzymatic activity. Degradation of GlcCer has been mainly studied for the lysosomal route: GlcCer reaches the lysosomes through the endosomal pathway and is degraded in the lysosome lumen by GBA1. Mutations in the Gba1 gene cause Gaucher disease -a severe lysosomal storage disorder characterised by accumulation of GlcCer in tissue macrophages (17, 18) . Although the activity of a nonlysosomal beta-glucosidase has been described as early as 1993 (13) , the mechanism and function of non-lysosomal GlcCer degradation is not well understood. GBA3 is a cytosolic, Klotho-related protein; members of this family share a beta-glucosidase-like domain (11, 12, 14) , but their physiological function is not known.
The other non-lysosomal beta-glucosidase GBA2 (15, 19) has been proposed to be a singlepass transmembrane protein with a long N terminus containing the beta-glucosidase domain followed by one transmembrane domain and a shorter C terminus (20) . Further studies suggest that (a) the C-terminal part is cytosolic and the N-terminal part is located either in the lumen of an organelle or on the extracellular side and (b) that GBA2 is located at or close to the cell surface (19) . GBA2 mRNA is rather ubiquitously expressed with higher levels in testis, brain, and liver (15) . GBA2-deficient mice accumulate GlcCer in particular in those tissues that express GBA2 most prominently. Accumulation of GlcCer has mainly two consequences: (a) male fertility is impaired due to the formation of aberrant sperm and (b) liver regeneration after partial hepatectomy is delayed (15, 21) . The mechanisms underlying these phenotypes are ill defined, because the signalling function of GlcCer is not well understood. In particular, the fate of non-lysosomal GlcCer, i.e. the dynamics and sites of synthesis and breakdown, is unknown.
Here, we have investigated the topology and localisation of GBA2 in heterologous and native systems and analysed beta-glucosidase activity in different tissues. Our results require major revision of existing concepts regarding the topology and localisation of GBA2, but also regarding the monitoring of GBA2 activity in particular and beta-glucosidase activity in general.
EXPERIMENTAL PROCEDURES
Cloning -The open reading frame of mouse GBA2 (NM_172692) was amplified from cDNA using specific primers containing restriction sites and a Kozak sequence in front of the start codon. The sequence encoding a hemagglutinin-tag (HA) was added by PCR either at the 5' or 3'end. PCR products were subcloned into pcDNA3.1+ (Invitrogen) and their sequence was verified. The resulting constructs were designated pc3.1-mGBA2-HA (GBA2-HA) and pc3.1-HAmGBA2 (HA-GBA2). To generate GBA2-eGFP fusion constructs, the open reading frame of mouse GBA2 was subcloned into pEGFP-N1 or pEGFP-C1 (Clontech), generating pEGFP-N1--GBA2 (eGFP-GBA2) and pEGFP-C1-mGBA2 (GBA2-eGFP), respectively.
Antibody generation -Peptides comprising amino acids (aa) 37-51 (peptide 1), aa 358-377 (peptide 2), aa 505-529 (peptide 3), aa 720-744 (peptide 4) from the murine GBA2 protein were synthesised and coupled to BSA and OVA (PSL, Heidelberg).
Rats were immunised subcutaneously and intraperitoneally with a mixture of 50 µg peptide-OVA, 5 nmol CPG oligonucleotide (Tib Molbiol), 500 µl PBS, and 500 µl incomplete Freund's adjuvant. A boost without adjuvant was given six weeks after the primary injection. Fusion was performed using standard procedures. Supernatants were tested in a differential ELISA with the respective GBA2 peptide and non-related peptides coupled to BSA. Monoclonal antibodies that reacted specifically with GBA2 were further analysed in Western blots (WB). Tissue culture supernatant of 4A12 rat IgG1 subclass were used for ICC and supernatants of 2H1 rat IgG2a, 2F8 rat IgG2b, and 5A8 rat IgG2a was used for WB (see Fig.  1A) .
Generation of stable cell lines -HEK293 cells were electroporated with pc3.1-mGBA2-HA or pc3.1-HA-mGBA2 using the Neon 100 µl kit (Invitrogen) and the MicroPorator (Digital Bio) according to the manufacture's protocol (3x 1245 mV pulses with 10 ms pulse width). Cells were transferred into complete medium composed of DMEM plus GlutaMax (Life Technologies GmbH) and 10 % fetal bovine serum (Biochrom). For the selection of monoclonal HEK293 cells stably expressing GBA2, the antibiotic G418 (800 µg/ml, Invitrogen) was added 24 h after electroporation. Monoclonal cell lines were identified by WB and immunocytochemistry using GBA2-specific antibodies.
Fibroblasts -Embryonic fibroblasts from Gba1-knockout mice were kindly provided by Ellen Sidransky (NIH, USA) (22) . Human control fibroblasts were a kind gift from Klaus Harzer (Tübingen University, Germany). Fibroblasts from a Gaucher patient were kindly provided by Mia Horowitz (Tel Aviv University, Israel). The patient displayed Gaucher disease type II with a L444P/P415R genotype.
Fibroblasts are grown in complete medium composed of DMEM, 2 mM L-glutamine, 1 mM sodium pyruvate, penicillin/streptomycin (all from Life Technologies GmbH), and 10 % FCS (Biochrom) at 37 °C and 5 % CO 2 in a humidified incubator.
Primary hippocampal neurons -Hippocampal neurons were prepared from embryonic mice at E17. Total brains were removed and placed in ice-cold HBSS (Life Technologies GmbH). Hippocampi were dissected and incubated in trypsin/EDTA for 8 min at 37 °C. The reaction was stopped by adding 10 ml plating medium (DMEM supplemented with 10 % horse serum, penicillin/streptomycin, L-glutamine, 1 mM sodium pyruvate). Hippocampi were washed and resuspended in HBSS by gently pipetting up and down. The suspension was diluted in plating medium and 80,000 cells were seeded on 13 mm glass coverslips coated with poly-D-lysine (Sigma, #P7886). Cells were grown in a humidified incubator at 37 °C with 5 % CO 2 . After 24 h, plating medium was exchanged for Neurobasal medium (supplemented with 1x B27 serum-free supplement, penicillin/streptomycin and GlutaMax). After 3 days in culture, 2 µM arabinosylcytosine (Sigma, #C1768) was added to the wells to inhibit growth of glial cells. Media and chemicals have been purchased from Life Technologies GmbH if not noted otherwise.
GBA2-deficient mice -The generation of GBA2-deficient mice has been described elsewhere (15) . All experiments involving animals were in accordance with the relevant guidelines and regulations.
Immunocytochemistry -Cells on glass coverslips were fixed for 10 min with 4 % paraformaldehyde in PBS. To block unspecific binding sites, cells were incubated for 30 min with blocking buffer (0.5 % Triton-X 100 and 5 % chemiblocker (Millipore, Germany) in 0.1 M phosphate buffer, pH 7.4). Primary antibodies were diluted in blocking buffer and incubated for 1 h at room temperature. After washing with PBS, cells were incubated with fluorescent secondary antibodies diluted in blocking buffer with 0.5 µg/µl DAPI (Invitrogen). After washing with PBS, cells were mounted on slides and examined with a confocal microscope (Olympus FV1000).
Antibodies -Primary antibodies: 4A12 Fluorescence protease protection assayFluorescence protease protection (FPP) assay has been performed as described elsewhere (23) . Images were taken with a 60x objective using the Olympus CellR.
Nocodazole treatment -To depolymerise microtubules, cells were incubated in DMEM complete medium containing 2.5 µg/ml nocodazole (Sigma). Cells were incubated at 37 °C, 5% CO 2 for 2.5 h. For repolymerisation, cells were washed with medium and incubated for 10 min at 37 °C, 5 % CO 2 .
Preparation of cell and tissue lysates -All steps are performed at 4 °C in the presence of mammalian protease inhibitor cocktail (Sigma Aldrich). Tissues or HEK293 cells were homogenised in hypotonic buffer (10 mM HEPES/NaOH, 0.5 mM EDTA at pH 7.4; 10 ml/g wet weight of the organ or cell pellet) by using an Ultra-Thurrax (IKA, Staufen, Germany) and three pulses (20 sec each) of sonification (Branson sonifier, Schwäbisch Gmünd, Germany). The suspension (total lysate) was centrifuged for 20 min at 1,000 × g. The supernatant (PNS, post-nuclear supernatant) was either used for activity assays or WB analysis.
Analysis of membrane association -PNS were washed three times with hypotonic buffer (10 mM HEPES/NaOH, 0.5 mM EDTA at pH 7.4) and two times with carbonate buffer (100 mM at pH 11.5) After each washing step, the suspension was centrifuged for 20 min at 541,000 x g av (TLA 100.3, Beckman). The membrane pellets obtained after each washing step were called P1 to P5, the corresponding supernatants S1 to S5. For Western blot analysis and activity assays, comparable amounts of each fraction were used.
Reconstitution experiments -Supernatants were prepared from hypotonic lysates (4 mg/ml protein) of brain from wild-type mice or from HEK293 cells over-expressing GBA2. P3 membrane pellets devoid of GBA2 were prepared from hypotonic lysates (4 mg/ml protein) of brain from GBA2-deficient mice or from HEK293 control cells. Furthermore, membranes were isolated from lysates (4 mg/ml protein) of bovine rod outer segments (bROS) as described elsewhere (24) . Preparation of artificial, protein-free membranes composed of soybean L-alpha-phosphatidylcholine (PC liposomes) has also been described elsewhere (25) . Briefly, 50 mg PC were solubilised in 5 ml hypotonic buffer containing 36 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and 5 mM dithiothreitol (DTT). CHAPS was removed by dialysis for 12 hours against an 800-fold volume excess of hypotonic buffer. Dialysis was repeated two times. S1 supernatants were mixed with either P3 pellets or bROS membranes. The final concentration of PC for reconstitution experiments was 1 mg/ml. Before performing the activity assay, the mixture of supernatants and membranes was incubated for 30 min at RT.
Western blot analysis -All samples were heated for 5 min at 95 °C prior to separation on SDS-PAGE. For WB analysis, proteins were transferred onto PVDF membranes, probed with antibodies, and analysed using the Odyssey Imaging System (Licor Biosciences).
Fluorescence-based GBA activity assaysThe activity of cellular GBAs was analysed using 4-methylumbelliferyl-beta-D-glucopyranoside (4-MU-beta-D-glucopyranoside, Sigma Aldrich) (26, 27) as a fluorescent substrate. Cleavage of 4-MU-beta-D-glucopyranoside was monitored in real-time in a Fluostar Omega reader (BMG labtech) at 29 °C using the filter pair 355 nm/460 nm for excitation and emission, respectively. The assays were performed in 384-well plates (Greiner) in the plate mode. Per well, 25 µl of lysate containing 5 to 10 µg of total protein were provided. To discriminate between GBA1 and GBA2 activity, CBE (Conduritol B epoxide, Sigma Aldrich), an inhibitor for GBA1, or NB-DNJ (N-butyldeoxynojirimycin, Sigma Aldrich), an inhibitor for GBA2, were included. The pH of protein lysates and the 4-MU-beta-Dglucopyranoside solution was adjusted by diluting with McIlvaine buffer. The assay was initiated by adding 5 µl of 4-MU-beta-Dglucopyranoside (10 mM) resulting in a final substrate concentration of 1.67 mM. The hydrolysis of 4-MU-beta-D-glucopyranoside was recorded as a change in relative fluorescence units (rfu) per minute. Each analysis was performed as a quadruplicate in parallel. Per genotype, tissues or cells from three animals were analysed if not otherwise stated. Data analysis was performed using Origin software (OriginLab).
RESULTS
Generation of GBA2-specific antibodies -An in-depth characterisation of GBA2 localisation was hampered so far by the lack of suitable antibodies. Therefore, we generated monoclonal antibodies against four different epitopes located in different regions of the GBA2 protein (Fig.  1A) . We tested the specificity of the antibodies by Western blot and immunocytochemistry using testes from GBA2 wild-type and knockout mice and from HEK293 cells expressing GBA2 fused to a hemagglutinin-tag (HA).
All GBA2 antibodies specifically detected the overexpressed protein in HEK293 lysates and the native protein in wild-type testis lysates; no protein was detected in lysates from HEK293 control cells or knockout testis (Fig. 1B) . The GBA2-specific antibody (4A12) and the HA antibody produced similar staining patterns in HEK293 cells over-expressing GBA2-HA (Fig.  1C) . Thus, these antibodies represent specific and sensitive tools for further studies.
GBA2 is a non-integral membrane-associated protein -It has been reported that GBA2 behaves like an integral membrane protein with its N terminus, containing the catalytic domain, being accessible to substrates in the extracellular space (19) . However, GlcCer is located in the inner leaflet of the plasma membrane, making it difficult to explain how GBA2 reaches the substrate. To solve this conundrum, we tested whether the N terminus of GBA2 is extracellulary located using a monoclonal antibody (4A12) raised against an N-terminal epitope (Fig. 1A) . In HEK293 cells overexpressing GBA2, the antibody detected the protein only in Triton X-100-permeabilized cells (Fig. 1D) . We corroborated this result using a fluorescence protease protection (FPP) assay (23) that allows determining the topology and localisation of fluorescent fusion proteins in living cells (Fig. 1E) . The FPP assay provides a fluorescent readout before and after protein degradation by trypsin. Under nonpermeabilising conditions, treatment with trypsin readily degrades protein moieties facing the extracellular side, but spares those facing the cytosolic side. To investigate whether the N terminus of GBA2 is facing the extracellular side, cells were imaged before and after trypsin treatment (4 mM, 1 min). As a control, HEK293 cells were transfected with YFP-PrP, a fusion between the GPI-anchored prion protein (PrP) and the yellow fluorescent protein (YFP). In the control, the distinctive fluorescence at the cell surface disappeared after trypsin treatment (Fig. 1E) . In contrast, cells expressing GBA2 with a green fluorescent protein (eGFP) attached to its N terminus showed no change in fluorescence after trypsin treatment (Fig. 1E) , indicating that the N terminus is not accessible from the extracellular side.
To test whether GBA2 is an integral membrane protein at all, we used a biochemical approach. Cells or tissues were lysed in hypotonic buffer, proteins were separated into soluble and membrane fractions, and tested for the presence of GBA2 by immunoblotting. GBA2 was detected in both membrane and soluble fractions (Fig. 1F) . Hypotonic washes resulted in the loss of GBA2 from the membrane fraction and recovery in the soluble fraction (Fig. 1F) . In HEK293 cells over-expressing GBA2, the protein was almost completely recovered in the soluble fraction after the first hypotonic wash, whereas in native tissue from brain, testis, and liver, hypotonic washes did not fully remove GBA2 from the membrane fraction. However, after a carbonate wash, which allows quantitative distinction between peripheral and integral membrane proteins (28), GBA2 was fully recovered in the supernatant (Fig. 1F ). These results demonstrate that GBA2 is not an integral membrane protein, but rather tightly associated with membranes.
GBA2 is localised at the ER and Golgi -To reveal where GBA2 is localised in a cell, we analysed GBA2 expression in HEK293 cells using different organelle markers. GBA2 was expressed in the cytosol, but its expression also spatially overlapped with calnexin, an ER marker; with GM130, a marker for the cis-Golgi network (CGN); and with giantin, a marker for the Golgi cisternae ( Fig. 2A) . When treating cells with nocodazole to depolymerise microtubules and disperse the Golgi, the GBA2 expressionpattern changed (Fig. 2B) , indicating that GBA2 localisation depends on microtubule dynamics. After Golgi dispersal, overlap of GBA2 and giantin expression persisted, at least partially, demonstrating that GBA2 co-segregates with Golgi compartments (Fig. 2B) . Upon repolymerisation, i.e. when the Golgi complex formed again, GBA2 still co-segregated with Golgi compartments (Fig. 2B) . Thus, GBA2 is localised at membranes of both the Golgi and the ER, i.e. structures that both rely on microtubule dynamics.
To investigate whether GBA2 is facing the lumenal or the cytosolic side of the ER, we performed a FPP assay under permeabilising conditions using fluorescently-tagged GBA2 constructs (Fig. 2C) . We used CD3δ-CFP and YFP-CD3δ as controls with the fluophore facing the cytosolic or lumenal side of the ER, respectively (23) (Fig. 2C ). Images were taken before and after permeabilisation with digitonin (20 µM, 1 min) and treatment with trypsin (4 mM, 1 min). The fluorescence of CD3δ-CFP readily changed after incubation with digitonin and trypsin, whereas the fluorescence of YFP-CD3δ did not change, indicating that only protein moieties facing the cytosolic side were degraded (Fig. 2C) . Under those conditions, the fluorescence of eGFP, which was either fused to the N or the C terminus of GBA2, was readily diminished, indicating that both termini are facing the cytosolic side (Fig. 2C) .
The expression pattern of GBA2, overexpressed in HEK293 cells, and of the native protein might be different. Therefore, we performed co-localisation studies using primary cells. The highest expression levels of GBA2 are observed in testis and brain (15) . In brain, GBA2 is expressed in all areas we tested: midbrain, olfactory bulb, cerebellum, hippocampus, and cortex (Fig. 3A) . We isolated hippocampal neurons from embryonic mice and differentiated the cells in a co-culture with astrocytes. GBA2 was expressed in neurons, but not in astrocytes (Fig. 3B) . The GBA2 expression pattern overlapped with the ER marker calnexin and the cis-Golgi marker GM-130, but not with giantin (Fig. 3C) . These results show that the endogenous GBA2 expression pattern in neurons and in heterologous systems is similar: GBA2 is localised at ER and Golgi membranes with the N-and C terminus facing the cytoplasm (for overview see Fig. 3D ).
Differential assay for GBA1 and GBA2 activity -To reveal the mechanism of nonlysosomal GlcCer breakdown, it is important to precisely distinguish between non-lysosomal GBA2 and lysosomal GBA1 activity. Standard assays used for more than 40 years contain detergents to probe the lysosomal GBA1 activity (29, 30) . Although GBA2 is highly expressed in murine liver (15) , beta-glucosidase activity in liver lysates towards 4-methylumbelliferyl-beta-D-glucopyranoside (4-MU-beta-D-glucopyranoside) under detergent-containing conditions (0.25 % Triton X-100, 0.25 % sodium taurocholate, 4 mM beta-mercaptoethanol, 0.5 mM EDTA) seemed to be solely due to GBA1 (Fig. 4A) . We measured pH profiles of beta-glucosidase activity in liver lysates in the absence or presence of CBE, a blocker for GBA1 activity (31) , and NB-DNJ, a blocker for GBA2 activity (32) . Whereas CBE reduced betaglucosidase activity, NB-DNJ had no pronounced effect (Fig. 4A) , suggesting that liver lysates contain GBA1, but no GBA2 activity. We were puzzled by this result and, therefore, scrutinised the assay under detergent-containing conditions using lysates from HEK293 cells over-expressing GBA2 (Fig. 4B) . Betaglucosidase activity in those cells was partially blocked by CBE or NB-DNJ (Fig. 4B) , indicating that both GBA1 and GBA2 activity contribute to the total beta-glucosidase activity. In the presence of both blockers, a residual activity between pH 4.5-7.5 was observed. These results show that both GBA1 and GBA2 activity can be measured under detergent-containing conditions. However, at pH 5.5-6.0, where GBA1 activity has been determined in the past (30, 33) , GBA1 and GBA2 activity overlap (Fig. 4B) . Thus, detergent-containing assay conditions do not allow to clearly distinguish between GBA1 and GBA2 activity, even in the presence of blockers.
To overcome this shortcoming, we tested various assay conditions to rigorously distinguish between lysosomal GBA1 and the non-lysosomal GBA2 activity in liver. We noticed that measuring beta-glucosidase activity in vitro in hypotonic lysates in the absence of detergent using 4-MU-beta-D-glucopyranoside allows delineating GBA1 and GBA2 activities according to their pH optimum. Under the new assay conditions, CBE completely blocked all beta-glucosidase activity at pH 4.0 in hypotonic lysates from liver. The remaining activity displayed an optimum at pH 5.0 -6.0 (Fig. 4C) . Vice versa, NB-DNJ blocked almost all betaglucosidase activity at pH 6.0, but not at pH 4.0 -4.5 (Fig. 4C) . In the presence of both blockers, no appreciable beta-glucosidase activity was measured (Fig. 4C) . Thus, GBA2 activity can be reliably monitored and its pH profile is distinct from that of GBA1. Therefore, GBA1 and GBA2 activities can be reliably distinguished in one and the same sample.
To confirm this result, we measured betaglucosidase activity in HEK293 cells overexpressing GBA2. NB-DNJ blocked a prominent activity around pH 6.0 (Fig. 4D) , whereas CBE blocked beta-glucosidase activity at pH 4.0 (Fig. 4D) . Again, in the presence of both blockers, no appreciable beta-glucosidase activity was measured (Fig. 4D ). These results demonstrate that the new assay conditions allow distinguishing between GBA1 and GBA2 activity according to their pH optimum around pH 4 and pH 6, respectively.
We observed three major differences when comparing our assay conditions with previous assay conditions. (i) In the absence of detergent, GBA1 and GBA2 activity display pH optima around pH 4 and pH 6, respectively. In the presence of detergent, however, the pH optimum for GBA1 activity was shifted to pH 5.5. As a consequence, between pH 5.5 -6.5, GBA1 and GBA2 activity considerably overlap, making it difficult to distinguish between the two activities.
(ii) In the absence of detergent, GBA2 activity is three times higher than in the presence of detergent. (iii) In the absence of detergent, GBA1 activity was two times lower than in the presence of detergent. In conclusion, the overlapping pH optima and the opposite action of detergents on GBA1 and GBA2 activities make previous assay unreliable to specifically identify the respective beta-glucosidase.
To fully characterise the blockers in the absence of detergent, we determined doseresponse relations for CBE and NB-DNJ using hypotonic lysates from mouse liver, brain, and testis. The IC 50 for CBE at pH 4 was similar between tissues, ranging from 2.5 to 3.4 µM, whereas beta-glucosidase activity at pH 6 was insensitive to CBE, indicating that the activity at pH 6 is independent of GBA1 (Fig. 4E) . The IC 50 for NB-DNJ in brain, testis, and liver at pH 6 was similar, ranging from 18.2 to 23.1 nM, whereas at pH 4, NB-DNJ did not affect betaglucosidase activity, indicating that the activity at pH 4 is independent of GBA2 (Fig. 4F) .
To compare the actions of CBE and NB-DNJ under our new and previously used assay conditions, we determined dose-response relations for both blockers in the presence and absence of detergent. Assays were performed at pH 4 and pH 6, which are optimal for GBA1 and GBA2 activity in the absence of detergent, and at pH 5.5, which has been previously used to determine beta-glucosidase activity in the presence of detergent (30, 33) . In the absence of detergent, CBE only blocked beta-glucosidase activity at pH 4.0 and not at pH 5.5 and pH 6.0 (Fig. 4G) , emphasising that under those conditions, GBA1 is only active around pH 4. In contrast, in the presence of detergent, CBE blocked beta-glucosidase activity at all pH values tested (Fig. 4G) , confirming that GBA1 activity displays a broadened and shifted pH profile in the presence of detergent. For NB-DNJ, it was not possible to determine an IC 50 at pH 4.0 under any condition, because GBA2 is inactive at pH 4 (Fig. 4H) . In the absence of detergent, at pH 5.5 and pH 6.0, the IC 50 was in the low nanomolar range (Fig. 4H) . The doseresponse curve was dramatically shifted to the right in the presence of detergent, resulting in IC 50 values in the micromolar range (Fig. 4H) . This shift could be explained either by NB-DNJ losing its potency in the presence of detergent or GBA1 or another beta-glucosidase activity being sensitive to micromolar concentrations of NB-DNJ. In summary, our assay takes advantage of the different pH optimum for GBA1 and GBA2 in the absence of detergent, which allows a reliable determination of each enzyme's activity.
Tissues differentially express GBA1 and GBA2 activity -We employed our assay to investigate beta-glucosidase activity in hypotonic lysates from brain, testis, and liver. All three tissues displayed activities with an optimum at pH 4.0 -4.5 (GBA1) and pH 5.5 -6.0 (GBA2, Fig. 5A ). GBA2 activity was highest in brain and lowest in liver (Fig. 5A) , whereas GBA1 activity was not dramatically different between tissues (Fig. 5A) . We have shown that GBA2 is rather ubiquitously expressed in different brain areas from mice (Fig. 3A) . In line with these results, GBA2 activity was also similar (Fig. 5B) .
GBA2 activity is down-regulated in GBA1-deficient fibroblasts -To identify whether there is a crosstalk between GBA1 and GBA2, we compared the activities in cells from different genotypes. First, we measured the pH profile of beta-glucosidase activity in brain, testis, and liver from GBA2-deficient mice. GBA2 activity at pH 6.0 was completely absent in these mice (Fig. 5C) . The activity at pH 4.0 was sensitive to CBE, showing that this residual activity solely represents GBA1 (Fig. 5C) . We compared GBA1 activity in wild-type and Gba2-knockout tissue and observed no obvious difference between genotypes (Fig. 5D) . However, because GBA1 activity is lower in the absence of detergent, we measured pH profiles in liver lysates from GBA2-deficient mice also in the presence of detergent: GBA1 activity was maximal at pH 5 and fully blocked by 30 µM CBE (Fig. 5E) . We compared GBA1 activity between wild-type and GBA2-deficient mice in the presence of detergent at pH 5. Similar to detergent-free conditions, GBA1 activity was not dramatically different between genotypes (Fig. 5F ).
Next, we performed the reverse experiment and measured GBA2 activity in the absence of detergent in fibroblasts from GBA1-deficient embryonic mice. GBA1 activity was absent, but also GBA2 activity was significantly reduced (Fig. 5G) . To identify whether this is due to the lack of GBA1 protein or the lack of GBA1 activity, we measured GBA2 activity in fibroblasts from a Gaucher patient with a type II phenotype and a L444P/P415R genotype. Here, GBA1 activity was dramatically reduced and again, GBA2 activity was also significantly decreased (Fig. 5H) . Our results suggest that GBA2 activity depends on GBA1, but GBA1 activity is independent of GBA2.
GBA2 activity depends on membrane association -Previous studies indicated that nonlysosomal beta-glucosidase activity is greatly diminished upon membrane disruption by detergents (13) . However, it is not clear whether this is due to removal of GBA2 from the membrane or a change of its enzymatic properties in the presence of detergent. Our new assay under detergent-free conditions allows to remove GBA2 from the membrane and measure its activity in the presence or absence of membranes. To analyse whether GBA2 activity requires association of the enzyme with the membrane, we determined GBA2 activity in the pellet and supernatant after hypotonic washes (Fig. 6A-C) . The activity in the total fraction after hypotonic lysis and in the low-speed supernatant (post-nuclear supernatant, PNS) was similar ( Fig. 6A-C) , suggesting that GBA2 activity was fully recovered in the PNS. After high-speed centrifugation of the PNS, the sum of GBA2 activity in the pellet (P1) and supernatant (S1) was considerably lower than that the total activity in the PNS (Fig. 6A-C) . In samples from testis and liver, GBA2 protein was almost entirely recovered in the pellet fraction (Fig. 1F) and in brain samples, GBA2 was about evenly distributed between the pellet and supernatant (Fig. 1F) . In contrast, the activity in the supernatant was at least 4-fold lower compared to that in the pellet (Fig. 6A-C) . Thus, the specific GBA2 activity in the supernatant was considerably lower than what was expected from the abundance of the GBA2 protein. These results suggest that full GBA2 activity requires either a co-factor that is removed upon washing or requires membrane association or both.
We distinguished between these possibilities by performing several experiments. First, we determined GBA2 activity in supernatants from different hypotonic lysates in the absence or presence of membranes from Gba2-knockout brain. In the supernatant from wild-type brain, GBA2 activity was low (Fig. 6D) . Addition of membranes from Gba2-knockout brain enhanced the activity 4-fold (Fig. 6D) . Similarly, in the supernatant from HEK293 cells over-expressing GBA2, the activity was enhanced 4-fold by membranes from Gba2-knockout brain (Fig. 6D) . Second, we determined GBA2 activity in the supernatants in the presence of membranes from bovine rod outer segment (ROS), which contain predominantly the molecules of the phototransduction cascade, but lack other cell organelles and the nucleus. GBA2 activity in supernatants from both wild-type brain and HEK293 cells over-expressing GBA2 was significantly enhanced by ROS membranes (Fig. 6D) . Third, to test whether phospholipids rather than a specific protein is responsible for the increase of GBA2 activity, we determined GBA2 activity in the presence of pure phosphatidylcholine (PC) liposomes (Fig. 6D) . GBA2 activity was enhanced 3-to 4-fold in the presence of PC liposomes. Furthermore, the activity was similar to that in the presence of membranes from wild-type brain, demonstrating that phospholipids themselves are sufficient to restore GBA2 activity to levels observed in the presence of native membranes.
DISCUSSION
Here, we provide several new insights into the function, activity, and localisation of the nonlysosomal GBA2.
First, GBA2 is not an integral membrane protein. However, it is tightly associated with membranes. One transmembrane segment was predicted from the protein sequence (20) . It has been reported that GBA2 is an integral membrane protein with the C terminus in the cytosol and the N terminus either outside the cell or in the lumen of a cell organelle (19) . Here, we demonstrate that the N-and C termini are directly accessible from the cytosol, ruling out any lumenal or extracellular localisation.
Consequently, the catalytic domain of GBA2 is also located on the cytosolic side of membranes.
Second, GBA2 is localised at the cytosolic surface of the ER and Golgi. The localisation of GBA2 at the Golgi, predominantly the cis-Golgi, implies that GBA2 activity is in close proximity to the site of GlcCer synthesis. Furthermore, sphingomyelin synthases (SMS), which convert ceramide derived from GlcCer to sphingomyelin (13) , are located at the Golgi (SMS1) or at the plasma membrane (SMS2) (34,35) . Thus, not only is GBA2 in close proximity to the site of GlcCer synthesis, but also to sites where ceramide is further processed. The localisation at the ER is in line with reports, suggesting that GBA2 is a resident ER protein (15, 16) . One model for GlcCer transport proposes that GlcCer reaches the ER through FAPP2-dependent transport and then flips to the ER lumenal side by low-specificity phospholipid flippases (8, 9) . In this model, GBA2 regulates GlcCer levels at the cytosolic side of the ER and, thereby, controls the amount of GlcCer that becomes available for higher-order glycosphingolipid synthesis. Taken together, its localisation puts GBA2 in a key position for a lysosomalindependent route of GlcCer-dependent signalling.
Third, our results indicate that GBA2 activity depends on the lipid environment of the membrane, consistent with the findings that the CBE-insensitive beta-glucosidase activity is lost upon membrane solubilisation (13) . Clearly, GBA2 must be present at the membrane, because the substrate GlcCer is either part of membranes or bound to proteins (FAPP2, GLTP). In our assays, we use 4-MU-beta-D-glucopyranoside as artificial substrate that, in contrast to GlcCer, is water-soluble. It would be desirable to perform future studies with a membrane-bound substrate that becomes fluorescent upon hydrolysis.
To hydrolyse GlcCer, GBA1 and GBA2 have to be recruited to the membrane. Binding to the integral membrane protein LIMP-2 in the Golgi governs targeting of GBA1 to the lysosomes (36) . Interaction of GBA1 with saposin C, a small glycoprotein that acts as enzymatic activator, recruits GBA1 to the membrane, thereby enabling hydrolysis of GlcCer (37) . For GBA2, however, specific interaction partners and the mechanism underlying the recruitment of GBA2 to cell membranes are not known.
Under our assay conditions, we could not detect any non-lysosomal, CBE-insensitive betaglucosidase activity at neutral pH other than GBA2 (Fig. 4B, C) . This is surprising, because GBA3 (EC 3.2.1.21, Klotho-related protein) has been identified as a non-lysosomal betaglucosidase that is ubiquitously expressed and operates in a similar pH range as GBA2 (11, 12, 14) . However, under detergent-containing conditions, an additional beta-glucosidase activity was observed (Fig. 4A, B) . To study the relative contribution of GBA3 activity in quantitative terms, GBA3-deficient mice are required. Unfortunately, these mice are not yet available.
Another important issue concerns a potential crosstalk between GBA1-and GBA2-dependent signalling pathways. Considering the distinct subcellular localisation of each enzyme, it is difficult to envision how the non-lysosomal and lysosomal pathways for GlcCer degradation interact with each other. Impairment of GBA1 activity (e.g. in Gaucher patients) results in accumulation of GlcCer in lysosomes of tissue macrophages causing liver and spleen enlargement and, in most severe cases, impairment of the central nervous system (38) . Gaucher disease is clinically heterogeneous and often classified into three principal subtypes: the non-neuronopathic type I, the acute neuronopathic type II, and the sub-acute neuronopathic type III (18) . It is not possible to predict the severity of Gaucher disease manifestation, because no clear genotypephenotype correlation exists (39, 40) . However, in a recent report, GBA2 activity was measured in Gaucher patients carrying the same mutations in the Gba1 gene, but displaying distinct clinical phenotypes (41) . Interestingly, GBA2 activity was different in those patients (41) . The authors suggest that measuring glucosidase activity in Gaucher disease patients may provide a valuable tool to refine the classification into distinct clinical subtypes. Our results demonstrate that GBA2 activity is decreased in both fibroblasts from a patient with Gaucher disease type II and from GBA1-deficient mice (see Fig. 5G, H) , suggesting a crosstalk between GBA1 and GBA2 that could affect the phenotype of Gaucher disease.
Taken together, our study contributes to the understanding of GBA2 function in mice and might help to unravel the role of GBA2 during pathogenesis of Gaucher disease.
